What We Offer
What We Promise
At Atherotech, every research study is carefully planned and conducted to accommodate the needs and expectations of our clients and study sponsors. We work diligently to meet client needs and deadlines, never compromising clinical excellence or data integrity.
What We Offer
MANAGEMENT
- Rigorous internal quality assurance
- Standard and custom data management
- A variety of distribution options – website, data file, fax, mail and custom
- Qualified, competent research staff
- Timely, accurate results
- Information confidentiality
TESTING
- The VAP© Cholesterol Test
- Triglycerides
- hs-CRP
- Homocysteine
- Testing of Both Human and Animal Specimens
- Testing of Fresh or Frozen (-70F) Specimens
- Testing of Serum or Plasma Specimens
How Does the VAP© Cholesterol Test Work?
The patented VAP© Test is a single comprehensive test for all lipoprotein classes and subclasses, and consists of the following three sequential steps:
1) separation of lipoprotein classes and their subclasses according to their density, using vertical spin density gradient ultracentrifugation
2) continuous enzymatic cholesterol analysis of separated lipoproteins using the VAP analyzer
3) quantification of lipoprotein classes and subclasses in terms of their cholesterol concentration by deconvoluting the total cholesterol profile obtained in step 2, using proprietary software
Thus the VAP© Test provides directly measured cholesterol concentrations of all major lipoprotein classes [HDL, LDL, VLDL, IDL, and Lp(a)] and their important subclasses, such as HDL2, HDL3, and LDL1 – LDL4. In addition, the VAP© Test also provides LDL subclass pattern (A, A/B or B) and remnant lipoprotein cholesterol.
For more details, please refer to the following references or contact us at 800.719.9807.
Clin Lab Med 2006;26:787-802 and J Lipid Res 1994;35:159-168.
“Atherotech has been a welcome professional partner in our study of differences in outcomes following acute myocardial infarction. We believe that with Atherotech’s help, we can create fundamental insights into the link between fatty acids and patient recovery outcomes following AMI.”
- John A. Spertus, MD, MPH
Director, CV Education and Outcomes Research
Mid America Institute at Saint Luke’s Hospital
Professor, School of Medicine, University of Missouri-Kansas City
